Pharmaceutical stocks have demonstrated remarkable resilience in 2026, with the Nifty Pharma index rising over 9% since January 1, significantly outperforming broader market indices that have remained under pressure. According to reports from ET Now, this strength reflects the sector's defensive characteristics, as pharmaceutical companies are typically considered stable investments due to consistent healthcare demand regardless of economic cycles. The sector's performance has been consistent across multiple timeframes, with 1-month gains of 9.40%, 3-month returns of 7.16%, and 6-month performance of 9.35%, demonstrating sustained investor interest amid ongoing market uncertainty.
Major brokerages have issued bullish recommendations for several pharmaceutical companies, with Zydus Lifesciences receiving the highest upside potential of 25% from Morgan Stanley with a target price of ₹1,311. As reported by ET Now, Sun Pharmaceutical Industries has an accumulate rating with a target of ₹2,085 from Elara Capital, representing a 13.3% upside. Aurobindo Pharma received a buy rating from Motilal Oswal with a target of ₹1,680, indicating a 16% upside potential. Torrent Pharmaceuticals received an equal-weight rating from Morgan Stanley with a target of ₹4,580, though this represents a 2.1% downside from current levels.
Zydus Lifesciences delivered strong Q4 results with EBITDA beating estimates by 14.5% despite higher R&D spending, according to Morgan Stanley reports. The company reported US revenues of USD 323 million while domestic formulations and consumer wellness revenues grew 13.9% and 61% year-on-year respectively. Management expects revenue growth in the high teens for FY27 with EBITDA margins above 24%. Sun Pharma showed Q4 specialty business growth of 20% year-on-year, with Leqselvi and Unloxcyt expected to drive growth in FY27, though weak US generics pricing remains a concern. Aurobindo Pharma maintained its highest gross margin in nine years, with strong European performance offsetting US weakness.
According to Motilal Oswal projections reported by ET Now, Aurobindo Pharma is expected to achieve revenue, EBITDA and PAT growth at a CAGR of 15%, 16% and 22% respectively over FY26-FY28. The company's future growth is anticipated to be driven by its US product pipeline, expansion in Europe, and the biologics business. Zydus Lifesciences management expects revenue growth in the high teens for FY27, while Torrent Pharmaceuticals noted that Q4 EBITDA came in line with estimates despite being the first quarter of JB Pharma consolidation, with the India business growing 15%.
